PMID- 23810246
OWN - NLM
STAT- MEDLINE
DCOM- 20140506
LR  - 20220311
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Print)
IS  - 0959-8049 (Linking)
VI  - 49
IP  - 15
DP  - 2013 Oct
TI  - Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with 
      pazopanib after disease progression with other targeted therapies.
PG  - 3169-75
LID - S0959-8049(13)00463-2 [pii]
LID - 10.1016/j.ejca.2013.06.003 [doi]
AB  - AIM: The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free 
      survival (PFS) versus placebo in treatment-naive and cytokine-refractory 
      metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with 
      pazopanib after targeted therapy (TT) are limited. METHODS: We retrospectively 
      evaluated records of consecutive patients with metastatic ccRCC who had 
      progressive disease (PD) after TT and received pazopanib from November 2009 
      through November 2011. Tumour response was assessed by a blinded radiologist 
      using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall 
      survival (OS) were estimated by Kaplan-Meier methods. RESULTS: Ninety-three 
      patients were identified. Median number of prior TTs was 2 (range, 1-5). There 
      were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial 
      response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months 
      (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated 
      transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting 
      (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 
      1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no 
      treatment-related deaths. CONCLUDING STATEMENT: Pazopanib demonstrated efficacy 
      in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was 
      mild/moderate and manageable.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Matrana, M R
AU  - Matrana MR
AD  - Hematology and Medical Oncology Fellowship Program, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Duran, C
AU  - Duran C
FAU - Shetty, A
AU  - Shetty A
FAU - Xiao, L
AU  - Xiao L
FAU - Atkinson, B J
AU  - Atkinson BJ
FAU - Corn, P
AU  - Corn P
FAU - Pagliaro, L C
AU  - Pagliaro LC
FAU - Millikan, R E
AU  - Millikan RE
FAU - Charnsangave, C
AU  - Charnsangave C
FAU - Jonasch, E
AU  - Jonasch E
FAU - Tannir, N M
AU  - Tannir NM
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - T32 CA009666/CA/NCI NIH HHS/United States
GR  - T32CA009666-15/CA/NCI NIH HHS/United States
GR  - 5 P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130626
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 7RN5DR86CK (pazopanib)
RN  - Clear-cell metastatic renal cell carcinoma
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Indazoles
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/administration & dosage/therapeutic use
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Retrospective Studies
MH  - Sulfonamides/adverse effects/*therapeutic use
PMC - PMC3882156
MID - NIHMS535552
OTO - NOTNLM
OT  - Angiogenesis
OT  - Mammalian target of rapamycin
OT  - Metastatic renal cell carcinoma
OT  - Pazopanib
OT  - Targeted therapy
OT  - Tyrosine kinase inhibitor
COIS- Conflict of Interest Statement Drs. Nizar Tannir and Eric Jonasch have research 
      funding and have participated in an Advisory Board Meeting with GlaxoSmithKline.
EDAT- 2013/07/03 06:00
MHDA- 2014/05/07 06:00
PMCR- 2014/01/06
CRDT- 2013/07/02 06:00
PHST- 2013/03/18 00:00 [received]
PHST- 2013/05/11 00:00 [revised]
PHST- 2013/06/03 00:00 [accepted]
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/05/07 06:00 [medline]
PHST- 2014/01/06 00:00 [pmc-release]
AID - S0959-8049(13)00463-2 [pii]
AID - 10.1016/j.ejca.2013.06.003 [doi]
PST - ppublish
SO  - Eur J Cancer. 2013 Oct;49(15):3169-75. doi: 10.1016/j.ejca.2013.06.003. Epub 2013 
      Jun 26.